Skip to main content

Table 2 Recurrence-free survival prognostic factors

From: Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation

Variable Recurrence-free survival
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Age 1.24 (0.98, 1.56) 0.068 1.19 (0.94, 1.51) 0.142
Male 0.94 (0.64, 1.36) 0.732   
Tumor number 1.47 (1.13, 1.91) < 0.001 1.32 (1.00, 1.73) 0.048
Tumor size 1.32 (1.18, 1.49) < 0.001 1.26 (1.11, 1.43) < 0.001
Risk area 1.20 (0.94, 1.53) 0.138   
AFP ≥200 ng/mL 1.25 (0.99, 1.57) 0.067 1.25 (0.98, 1.58) 0.067
Pre-TACE 1.23 (0.96, 1.58) 0.097 1.07 (0.82, 1.40) 0.606
PLT < 100 × 109/L 1.28 (1.02, 1.60) 0.032 1.18 (0.93, 1.84) 0.169
RBC < 4.3 × 109/L 1.00 (0.79, 1.26) 0.975   
WBC < 4.0 × 109/L 1.20 (0.93, 1.56) 0.161   
ALB < 35 g/L 1.48 (1.07, 2.06) 0.019 1.30 (0.92, 1.84) 0.133
ALT < 50 U/L 1.00 (0.78, 1.28) 0.990   
AST < 40 U/L 1.07 (0.85, 1.35) 0.578   
TBIL > 17.1 μmol/L 1.01 (0.96, 1.07) 0.695   
PT > 16.5 s 0.80 (0.40, 1.63) 0.545   
Cirrhosis 1.12 (0.88, 1.57) 0.263   
  1. Abbreviations: AFP alpha-fetoprotein, TACE transcatheter arterial chemoembolization, PLT platelet, RBC red blood cell, WBC white blood cell, ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, TBIL total bilirubin, PT prothrombin time
  2. Variables with P value < 0.10 at univariate analysis were retained for multivariate analysis